The shortage explanation needs a date
GLP-1 medicines imitate the action of a hormone involved in blood sugar and appetite.
As of September 2026, semaglutide injections and tirzepatide injections were both absent from FDA’s national shortage list.
FDA is the Food and Drug Administration.
Empty stock at one local pharmacy does not amount to a listing for a national shortage.
For medicines listed on FDA’s national shortage list, the law can permit pharmacies to make copies. Once it leaves that list, the shortage no longer gives that permission.
As of September 2026, FDA said a semaglutide preparation could remain essentially a copy of an available product even with a vitamin added.
Do not let generic mean compounded
As of September 2026, there was no approved generic semaglutide or tirzepatide that could be sold in the US.
A generic is an approved copy of a branded medicine; compounding makes medicine to fill an order.
As of September 2026, FDA had received reports of errors in measuring compounded semaglutide, including reports involving hospital stays.
These reports raise a concern; they do not prove that the medicine caused every reported problem.
- What need of mine is the change meant to meet?
- Is the shortage claim current?
- What exactly does the service mean by generic?
- Who explains the product instructions and handles questions?
Ask the clinician or pharmacist to explain unclear instructions. Do not use a webpage to work out how different measuring terms match up or how much medicine to use.
Notes behind the answers
- FDA · shortage and copy policies
The source for shortage status and the vitamin-added example.
- FDA · approval application records
Check whether a generic has full approval to be sold. An application alone does not mean it is available.
- FDA · reported measuring errors
The alert about reports involving measuring errors and hospital care.
- FDA · what reports can show
A report by itself does not prove the event was caused by the medicine.